| Zydus Lifesciences Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 532321 |
NSE Symbol : ZYDUSLIFE |
P/E(TTM) : 24.31 |
|
ISIN Demat : INE010B01027 |
Div & Yield% : 0.28 |
EPS(TTM) : 43.41 |
|
Book Value(₹) : 156.19 |
Market Cap(₹Cr) : 106,197.94 |
Face Value(₹) : 1.00 |
| Particulars | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | 10,818.70 | 8,731.60 | 7,836.90 | 7,780.00 | 6,347.40 |
| Excise Duty | - | - | - | - | - |
| Net Sales | 10,818.70 | 8,731.60 | 7,836.90 | 7,780.00 | 6,347.40 |
| Other Income | 1,084.80 | 548.40 | 178.70 | 89.30 | 908.70 |
| Stock Adjustments | 131.70 | -105.10 | 46.90 | 148.30 | -15.50 |
| Total Income | 12,035.20 | 9,174.90 | 8,062.50 | 8,017.60 | 7,240.60 |
| EXPENDITURE : | |||||
| Raw Materials | 3,284.60 | 3,066.20 | 2,917.10 | 2,499.70 | 1,936.20 |
| Power and Fuel Cost | 298.20 | 278.60 | 245.20 | 193.20 | 208.40 |
| Other Manufacturing Expenses | 347.20 | 332.50 | 381.10 | 363.40 | 327.30 |
| Selling and Administration Expenses | 1,016.00 | 1,039.80 | 958.40 | 1,009.10 | 925.30 |
| Miscellaneous Expenses | 446.80 | 336.90 | 578.30 | 594.40 | 486.20 |
| Employee Benefit Expenses | 1,507.50 | 1,321.90 | 1,204.90 | 1,147.30 | 1,077.40 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 5,134.90 | 2,799.00 | 1,777.50 | 2,210.50 | 2,279.80 |
| Interest | 390.70 | 278.20 | 134.90 | 70.90 | 233.90 |
| Gross Profit | 4,744.20 | 2,520.80 | 1,642.60 | 2,139.60 | 2,045.90 |
| Depreciation | 504.40 | 488.60 | 478.70 | 451.10 | 428.90 |
| Profit Before Tax | 4,239.80 | 2,032.20 | 1,163.90 | 1,688.50 | 1,617.00 |
| Current Tax | 934.30 | 461.80 | 260.20 | 303.30 | 164.10 |
| Fringe Benefit tax | - | - | - | - | - |
| Deferred Tax | -136.00 | 41.20 | 45.80 | -91.00 | 40.00 |
| Reported Net Profit | 3,441.50 | 1,529.20 | 857.90 | 1,476.20 | 1,412.90 |
| Extraordinary Items | 3.90 | -92.27 | -237.64 | -156.95 | -52.67 |
| Adjusted Net Profit | 3,437.60 | 1,621.47 | 1,095.54 | 1,633.15 | 1,465.57 |
| Adjustment below Net Profit | -54.00 | 1.80 | -6.90 | -15.30 | -6.00 |
| Profit/Loss Balance carried down | 10,567.40 | 9,289.40 | 8,796.90 | 7,336.00 | 6,645.70 |
| Statutory Appropriations | - | - | - | - | - |
| Appropriations | 607.30 | 253.00 | 358.50 | - | 716.60 |
| P & L Balance carried down | 13,347.60 | 10,567.40 | 9,289.40 | 8,796.90 | 7,336.00 |
| Dividend | - | - | - | - | - |
| Preference Dividend | - | - | - | - | - |
| Equity Dividend (%) | 300.00 | 600.00 | 250.00 | 350.00 | 350.00 |
| Dividend Per Share(Rs) | 3.00 | 6.00 | 2.50 | 3.50 | 3.50 |
| Earnings Per Share-Unit Curr | 34.21 | 15.11 | 8.38 | 14.42 | 13.80 |
| Earnings Per Share(Adj)-Unit Curr | 34.21 | 15.11 | 8.38 | 14.42 | 13.80 |
| Book Value | 156.23 | 134.78 | 129.30 | 124.46 | 109.96 |
| Book Value(Adj)-Unit Curr | 156.23 | 134.78 | 129.30 | 124.46 | 109.96 |